
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is expected to post strong results in the first quarter of 2026, with product sales and operating margin being the lowest of the year due to inventory build and generic competition, but emerging therapies such as MariTide and olpasiran may provide upside. However, the company also faces headwinds from biosimilar/generic competition and potential pricing/regulatory risks, leading to a steady but limited expected revenue growth range of $36-$38 billion until 2030. Upside risks include strong performance from growth products and positive pipeline data, while downside risks include product and regulatory risks and increased concerns in the biopharma industry.
Bears say
Amgen is facing upcoming patent expiries for its key franchises and its limited pipeline visibility may require continued business development for sustained topline growth. On the other hand, their current products and pipeline show high clinical potential and with the assumption of consistent data and targeted readout in 4Q26, they may reach total revenues of $42.0B+ by 2030. However, the limited window into their next major growth drivers leaves the stock fairly valued and warrants a Hold rating with a price target of $318.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares